Trial Profile

A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilotumumab (Primary) ; Mitoxantrone; Prednisone
Indications Prostate cancer
Focus Adverse reactions; Biomarker; Therapeutic Use
Sponsors Amgen

Most Recent Events

14 Oct 2021 This trial has been completed in France (Global end date: 30 Apr 2012).
04 Feb 2012 Results presented at the 2012 Genitourinary Cancers Symposium.
08 Sep 2011 Planned end date changed from 1 Mar 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com